OrbiMed’s Axsome Therapeutics AXSM Stock Holding History

OrbiMed’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36.2M	Sell	213,921 -39,200	-15%	-$6.77M	0.72%	42
2025 Q4	$46.2M	Sell	253,121 -278,679	-52%	-$38.9M	0.94%	32
2025 Q3	$64.6M	Buy	531,800 +103,900	+24%	+$11.7M	1.52%	20
2025 Q2	$44.7M	Buy	427,900 +41,200	+11%	+$4.36M	1.12%	27
2025 Q1	$45.1M	Buy	+386,700	New	+$44.1M	1.08%	27

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's AXSM Position: Q1 2026 in Review

OrbiMed reduced its Axsome Therapeutics (AXSM) stake by 15% in Q1 2026, selling an estimated $6.77M and leaving 213,921 shares worth $36.2M. The position accounts for 0.72% of the portfolio, ranked #42.

OrbiMed first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. The position peaked at $64.6M in Q3 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

OrbiMed held 213,921 shares of Axsome Therapeutics worth $36.2M as of Q1 2026.
OrbiMed sold 39,200 Axsome Therapeutics shares in Q1 2026, an estimated $6.77M.
Axsome Therapeutics made up 0.72% of OrbiMed's portfolio in Q1 2026, its #42 holding.
OrbiMed first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
OrbiMed's Axsome Therapeutics position peaked at $64.6M in Q3 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.